Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a Granulocyte colony-stimulating factor presented as an injectable solution for intravenous or subcutaneous use. It is used to stimulate neutrophil production in patients who develop neutropenia after chemotherapy, bone‑marrow transplantation, or who have chronic neutropenia. GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen is a granulocyte colony‑stimulating factor indicated for several neutropenia‑related conditions. - Chemotherapy‑induced neutropenia: shortens the duration of low neutrophil counts and reduces infection risk in patients receiving cytotoxic chemotherapy. - Severe chronic neutropenia: increases neutrophil production to help maintain protective immune levels in patients with persistent neutropenia. - Neutropenia following bone marrow transplantation: supports rapid neutrophil recovery after transplant procedures. - Peripheral blood stem cell mobilization for autologous transplantation: enhances mobilization of stem cells into the peripheral blood for collection.

Neupogen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bone pain: discomfort in the limbs or back, often related to rapid marrow expansion. - Injection‑site reactions: redness, swelling, or tenderness at the administration site. - Fever or chills: transient elevations in body temperature. - Headache: mild to moderate intensity. - Nausea or fatigue: general feeling of unease or tiredness.

Serious or Rare Side Effects: - Splenic rupture or enlargement: rare but potentially life‑threatening abdominal emergency. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty requiring immediate medical attention. - Anaphylaxis or severe allergic reactions: rapid onset of hives, swelling, or airway compromise. - Capillary leak syndrome: sudden fluid shift causing low blood pressure and edema.

Before initiating Neupogen, clinicians should consider several safety measures. - Monitor blood counts: assess neutrophil levels regularly to gauge response. - Assess splenic size: perform imaging if abdominal pain occurs to detect enlargement. - Use caution in sickle cell disease: increased risk of vaso‑occlusive events. - Avoid in patients with known hypersensitivity to filgrastim or any excipients. - Adjust dosing in renal impairment: consider reduced clearance in severe kidney disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other agents that affect bone‑marrow function or immune response.

Major Interactions (Avoid): - Concurrent use with other G‑CSF agents (e.g., sargramostim): may amplify bone pain and splenic enlargement. - Combination with high‑dose cytotoxic chemotherapy that profoundly suppresses marrow: can diminish filgrastim’s efficacy.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may blunt neutrophil response, requiring closer monitoring. - Live vaccines: reduced vaccine efficacy; schedule vaccinations appropriately. - Certain antibiotics (e.g., beta‑lactams): no direct pharmacokinetic interaction but monitor infection status closely.